Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001129928-25-000089
Filing Date
2025-11-12
Accepted
2025-11-12 17:28:54
Documents
6
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 6-K q32025form6-k.htm 6-K 22126
2 EX-99.1 2025 THIRD QUARTER INTERIM FINANCIAL STATEMENTS ex991-interimfsseptember30.htm EX-99.1 418687
3 EX-99.2 2025 THIRD QUARTER MD&A ex992-q32025mda.htm EX-99.2 256878
4 EX-99.3 ex993-q32025certificationx.htm EX-99.3 14032
5 EX-99.4 ex994-q32025certificationx.htm EX-99.4 13976
6 oncolyticslogotaglineblueaa.jpg GRAPHIC 355294
  Complete submission text file 0001129928-25-000089.txt   1166223
Mailing Address 804, 322 - 11 AVENUE SW CALGARY Alberta, Canada
Business Address 804, 322 - 11 AVENUE SW CALGARY Alberta, Canada 4036707377
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38512 | Film No.: 251474447
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)